期刊
VACCINE
卷 28, 期 26, 页码 4249-4259出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.04.020
关键词
Streptococcus pneumoniae; Serotype 19A; Pneumococcal conjugate vaccines
资金
- Wyeth Pharmaceuticals, Collegeville, PA
- Wellcome Trust
- GlaxoSmithKline Pharmaceuticals
- Wyeth Ayerst-Lederle Pharmaceuticals
- Pfizer Inc
Streptococcus pneumoniae serotype 19A is associated with all forms of pneumococcal disease and was the first reported pneumococcal serotype with high-level penicillin and multidrug resistance. While the seven-valent pneumococcal conjugate vaccine (PCV7), which contains serotype 19F, has reduced rates of disease among children and adults, the incidence of disease due to nonvaccine and increasingly drug-resistant serotypes - predominantly serotype 19A - has increased. This review summarizes the published literature to analyze the factors contributing to the emergence of serotype 19A, the diseases associated with this serotype, and the importance of including this serotype in novel pneumococcal conjugate vaccines. A recently approved 13-valent vaccine includes this serotype, and is likely to significantly reduce the burden of disease due to serotype 19A. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据